<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01906580</url>
  </required_header>
  <id_info>
    <org_study_id>2011030D</org_study_id>
    <nct_id>NCT01906580</nct_id>
  </id_info>
  <brief_title>Combination or Sequential Therapy of Peginterferon Alfa-2a and Entecavir for Patients With Chronic Hepatitis B</brief_title>
  <official_title>Combination or Sequential Therapy of Peginterferon Alfa-2a and Entecavir for Hepatitis B e Antigen-positive Patients With Chronic Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing 302 Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing 302 Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently, seven medications are approved for the treatment of hepatitis B: two formulations
      of interferon and five nucleons(t)ide analogues. The current treatment strategy of chronic
      hepatitis B is now standard: initial selection of entecavir, tenofovir, or peginterferon
      alfa-2a (peg-IFNα-2a). Interferon is administered for a finite duration while nucleotide
      analogues are usually administered for many years. But among hepatitis B e antigen （HBeAg）
      positive patients with high serum hepatitis B virus DNA levels, the rates of virological
      response are poor. And antiviral drug resistance is a major limiting factor to the success of
      nucleotide analogue treatment. Therefore, combination therapy using peginterferon with an
      oral agent with a high genetic barrier to resistance might be superior to standard current
      monotherapy. However, the addition of lamivudine to peg-IFNα-2a therapy led to a greater
      decrease in serum HBV DNA levels during treatment but did not increase the rate of HBeAg
      sero¬conversion. Entecavir is a nucleoside analogue superior to lamivudine and adefovir in
      achieving higher virological response, histological improvement and normalisation of ALT.
      Moreover, Entecavir has a high genetic barrier with a very low incidence of drug resistance.
      This study is aimed to investigate the efficacy of combination or sequential therapy using
      peg-IFNα-2a and entecavir in HBeAg-positive chronic hepatitis B(CHB) patients.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the rates of HBeAg seroconversion</measure>
    <time_frame>at week 72</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>normalisation of ALT</measure>
    <time_frame>at week 2、4、12、24、36、48、60、72、84、96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>liver histological improvement</measure>
    <time_frame>at baseline and at week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rates of HBsAg negative</measure>
    <time_frame>at week12、24、36、48、60、72、84、96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the rate of virological response</measure>
    <time_frame>at week 4、12、24、36、48、60、72、84、96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the rate of HBeAg negative</measure>
    <time_frame>at week 12、24、36、48、60、72、84、96</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Peg-IFNα-2a monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 180ug peg-IFNα-2a therapy for 72 weeks, and then followed to 96 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequential therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive entecavir monotherapy for 12 weeks, and 180ug peg-IFNα-2a therapy is added for the following 12 weeks. After that, entecavir will be stopped and 180ug peg-IFNα-2a monotherapy for the following 48 weeks. All participants will followed to 96 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 180ug peg-IFNα-2a combined with entecavir therapy for 72 weeks, and then followed to 96 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peg-IFNα-2a</intervention_name>
    <description>180ug peg-IFNα-2a, subcutaneous injection per week</description>
    <arm_group_label>Peg-IFNα-2a monotherapy</arm_group_label>
    <arm_group_label>Sequential therapy</arm_group_label>
    <arm_group_label>Combination therapy</arm_group_label>
    <other_name>peginterferon alfa-2a</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir</intervention_name>
    <description>0.5mg,oral administration every day</description>
    <arm_group_label>Sequential therapy</arm_group_label>
    <arm_group_label>Combination therapy</arm_group_label>
    <other_name>Baraclude</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age≥16 years

          2. HBsAg positive for more than 6 months, and HBeAg detection is positive for two times
             in 6 months before enrollment

          3. Serum HBVDNA ＞2×10^4IU/ml

          4. 80U/L &lt; serum ALT &lt; 400U/L, and TBIL &lt; 34 umol/L

          5. Serum ALT &lt; 80U/L, but hepatic inflammation scores ≥ G2 or hepatic fibrosis stage ≥ S3

        Exclusion Criteria:

          1. Co-infected with HCV, HDV or HIV, or autoimmune liver diseases combined

          2. Hepatic decompensation

          3. received antiviral therapy or immunosuppressant drugs before 6 months prior to
             enrollment

          4. Blood routine examination: WBC ＜3×10^9/L，neutrophile granulocyte ＜ 1.5×10^9/L，PLT
             ＜80×10^9/L

          5. Renal function: creatinine ＞1.5 times of upper normal limit

          6. Alcoholism or a history of addiction and abuse

          7. Combined with hepatocarcinoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fu-Sheng Wang, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing 302 Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sa Lv, MD</last_name>
    <phone>86-10-63879735</phone>
    <phone_ext>2014.12</phone_ext>
    <email>lvsa@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Center for Biological Therapy, The Institute of Translational Hepatology, Beijing 302 Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100039</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sa Lv, MD</last_name>
      <phone>86-10-63879735</phone>
      <phone_ext>2015.12</phone_ext>
      <email>lvsa@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Kwon H, Lok AS. Hepatitis B therapy. Nat Rev Gastroenterol Hepatol. 2011 May;8(5):275-84. doi: 10.1038/nrgastro.2011.33. Epub 2011 Mar 22. Review.</citation>
    <PMID>21423260</PMID>
  </reference>
  <reference>
    <citation>Ayoub WS, Keeffe EB. Review article: current antiviral therapy of chronic hepatitis B. Aliment Pharmacol Ther. 2011 Nov;34(10):1145-58. doi: 10.1111/j.1365-2036.2011.04869.x. Epub 2011 Oct 7. Review.</citation>
    <PMID>21978243</PMID>
  </reference>
  <reference>
    <citation>Kuo A, Gish R. Chronic hepatitis B infection. Clin Liver Dis. 2012 May;16(2):347-69. doi: 10.1016/j.cld.2012.03.003. Review.</citation>
    <PMID>22541703</PMID>
  </reference>
  <reference>
    <citation>Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol. 2005 Mar;5(3):215-29. Review.</citation>
    <PMID>15738952</PMID>
  </reference>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2013</study_first_submitted>
  <study_first_submitted_qc>July 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2013</study_first_posted>
  <last_update_submitted>August 14, 2015</last_update_submitted>
  <last_update_submitted_qc>August 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HBV</keyword>
  <keyword>entecavir</keyword>
  <keyword>peginterferon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

